Reducing proinflammatory response

Patent metadata

Field	Value
Publication number	US-9352020-B2
Application number	US-201313838539-A
Country	US
Kind code	B2
Filing date	Mar 15, 2013
Priority date	Mar 15, 2013
Publication date	May 31, 2016
Grant date	May 31, 2016

Abstract

The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.

First claim

What is claimed is:

1. A method for reducing the levels of pro-inflammatory cytokines in the plasma of a target subject, comprising the step of administering a nutritional composition comprising a carbohydrate source, a fat or lipid source, and a protein equivalent source, wherein the protein equivalent source comprises a peptide component comprising: SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 26, SEQ ID NO: 33, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO:60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 68.

2. The method of claim 1 , wherein the peptide component comprises at least 10 additional peptides selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 63, and SEQ ID NO: 66.

3. The method of claim 1 , wherein the peptide component comprises at least 20 additional peptides selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 63, and SEQ ID NO: 66.

4. The method according to claim 1 , wherein the nutritional composition comprises about 0.1 to about 1 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide.

5. The method of claim 1 , wherein the nutritional composition comprises at least one long chain polyunsaturated fatty acid.

6. The method of claim 5 , wherein the at least one long chain polyunsaturated fatty acid is present in an amount of from about 5 mg/100 kcal to about 100 mg/100 kcal.

7. The method of claim 5 , wherein the at least one long chain polyunsaturated fatty acid is selected from the group consisting of docosahexaenoic acid, arachidonic acid, and combinations thereof.

8. The method according to claim 1 , wherein the target subject is an infant.

9. The method according to claim 1 , wherein the target subject is a child or juvenile.

10. The method according to claim 1 , wherein the target subject has at least one inflammatory disease, wherein the inflammatory disease is selected from the group consisting of type 1 diabetes, Crohn's disease, Ulcerative colitis, metabolic syndrome, HLA-DQ8 related diseases, HLA-DQ2 related diseases, and Coeliac disease.

11. The method according to claim 1 , wherein the composition comprises one or more of nucleic acids, lipids, minerals, anabolic nutrients, vitamins, antioxidants, probiotic bacterial strains, and lipotropic agents.

12. The method according to claim 1 , wherein the target subject has cow's milk allergy.

13. A method for increasing butyric acid concentration in the gastrointestinal tract of a target subject, comprising the step of administering a nutritional composition comprising a carbohydrate source, a fat or lipid source, and a protein equivalent source, wherein the protein equivalent source comprises a peptide component comprising: SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 26, SEQ ID NO: 33, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO:60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 68.

14. The method of claim 13 , wherein the peptide component comprises at least 10 additional peptides selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 63, and SEQ ID NO: 66.

15. The method of claim 13 , wherein the peptide component comprises at least 20 additional peptides selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 63, and SEQ ID NO: 66.

16. The method according to claim 13 , wherein the nutritional composition comprises about 0.1 to about 1 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide.

17. The method of claim 13 , wherein the nutritional composition comprises at least one long chain polyunsaturated fatty acid.

18. The method of claim 14 , wherein the at least one long chain polyunsaturated fatty acid is present in an amount of from about 5 mg/100 kcal to about 100 mg/100 kcal.

19. The method according to claim 14 , wherein the target subject is an infant.

20. The method according to claim 13 , wherein the target subject has at least one inflammatory disease, wherein the inflammatory disease is selected from the group consisting of type 1 diabetes, Crohn's disease, Ulcerative colitis, metabolic syndrome, HLA-DQ8 related diseases, HLA-DQ2 related diseases, and Coeliac disease.

Assignees

• Mead Johnson Nutrition Asia Pacific Pte Ltd
• Mead Johnson Nutrition Co

Inventors

• Hondmann Dirk
• Van Tol Eric A F
• Gross Gabriele
• Schoemaker Marieke H
• Lambers Teartse Tim

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title